---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-07
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla
run_number: 7
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 701
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-07.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 07)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla`, run 7 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 701, on the frozen condition packet.

## Output

**Recommendation: Run the Claim File Review.**

**Why:**
Your current growth signals are "false positives" driven by financial engineering (bundle pricing) and sales narratives (roadmap promises), not product value. The 39% usage spike is an illusion; it is driven by managers performing audits, not adjusters performing work.

You are facing a critical "Value Gap": front-line users abandon the tool unless supervised, and health-liability users cannot justify its output to regulators. If you scale now, you are scaling a liability that will trigger massive churn once procurement windows open. The *Usage Quality Sprint* only measures *if* they use it (which you already know is superficial), and the *Commercial Cleanroom* measures *if* they will pay for it (which is irrelevant if the product doesn't actually work). The *Claim File Review* is the only option that identifies *why* it is being overridden or abandoned. It converts "enthusiastic comments" into hard data on accuracy and explainability, allowing you to fix the product before the renewal cliff hits.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation tests. While a dashboard (Sprint) or a sales experiment (Cleanroom) provides immediate quantitative data, the File Review requires manual effort from adjusters and reviewers. In a twelve-day window to lock the budget, this approach risks providing "anecdotal" qualitative data rather than a statistically significant "green light" for the board.

**Observable evidence that would change my mind:**
If you discover that the "manual overrides" in health-liability are not due to a failure of the AI’s logic, but are instead caused by a missing UI field for "Regulatory Justification." If the problem is a simple documentation gap rather than a core logic/trust failure, I would pivot to the **Usage Quality Sprint** to quickly validate if a simple UI fix restores the adjuster return rate.
